MA30298B1 - Composition - Google Patents
CompositionInfo
- Publication number
- MA30298B1 MA30298B1 MA30238A MA30238A MA30298B1 MA 30298 B1 MA30298 B1 MA 30298B1 MA 30238 A MA30238 A MA 30238A MA 30238 A MA30238 A MA 30238A MA 30298 B1 MA30298 B1 MA 30298B1
- Authority
- MA
- Morocco
- Prior art keywords
- oil
- water emulsion
- vaccine formulations
- immunization
- mpl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention porte sur des formulations de vaccin antigrippal et des schémas posologiques de vaccination permettant l'immunisation contre diverses maladies. Cette invention concerne en particulier des formulations de vaccin renfermant un adjuvant d'émulsion huile-dans-eau et un 3D-MPL, leur utilisation en médecine, en particulier leur utilisation pour accroître les réponses immunitaires à divers antigènes, ainsi que des méthodes de préparation, laquelle émulsion huile-dans-eau comprend un stérol, une huile métabolisable et un agent émulsifiant.
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0505998A GB0505998D0 (en) | 2005-03-23 | 2005-03-23 | Novel compositions |
GB0506001A GB0506001D0 (en) | 2005-03-23 | 2005-03-23 | Novel use |
GB0506000A GB0506000D0 (en) | 2005-03-23 | 2005-03-23 | Novel use |
GB0506004A GB0506004D0 (en) | 2005-03-23 | 2005-03-23 | Compositions |
GB0505989A GB0505989D0 (en) | 2005-03-23 | 2005-03-23 | Compositions |
GB0510596A GB0510596D0 (en) | 2005-05-24 | 2005-05-24 | Composition |
GB0510589A GB0510589D0 (en) | 2005-05-24 | 2005-05-24 | Novel use |
GB0510598A GB0510598D0 (en) | 2005-05-24 | 2005-05-24 | Composition |
GB0510591A GB0510591D0 (en) | 2005-05-24 | 2005-05-24 | Novel use |
GB0510593A GB0510593D0 (en) | 2005-05-24 | 2005-05-24 | Novel compositions |
GB0603789A GB0603789D0 (en) | 2006-02-24 | 2006-02-24 | Novel use |
GB0603788A GB0603788D0 (en) | 2006-02-24 | 2006-02-24 | Novel composition |
GB0603790A GB0603790D0 (en) | 2006-02-24 | 2006-02-24 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30298B1 true MA30298B1 (fr) | 2009-04-01 |
Family
ID=36441219
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30238A MA30298B1 (fr) | 2005-03-23 | 2007-09-24 | Composition |
MA30240A MA29715B1 (fr) | 2005-03-23 | 2007-09-24 | Utilisation d'un virus de la grippe et d'un adjuvant de type emulsion huile dans l'eau pour induire une cellule t cd-4 et/ou ameliorer la reponse de la cellule a memoire b |
MA30241A MA29342B1 (fr) | 2005-03-23 | 2007-09-24 | Nouvelle composition |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30240A MA29715B1 (fr) | 2005-03-23 | 2007-09-24 | Utilisation d'un virus de la grippe et d'un adjuvant de type emulsion huile dans l'eau pour induire une cellule t cd-4 et/ou ameliorer la reponse de la cellule a memoire b |
MA30241A MA29342B1 (fr) | 2005-03-23 | 2007-09-24 | Nouvelle composition |
Country Status (24)
Country | Link |
---|---|
US (5) | US20080181911A1 (fr) |
EP (4) | EP2397153A1 (fr) |
JP (4) | JP5869744B2 (fr) |
KR (5) | KR20070116651A (fr) |
AR (3) | AR054020A1 (fr) |
AU (3) | AU2006226543B2 (fr) |
CA (3) | CA2602456A1 (fr) |
CY (1) | CY1117874T1 (fr) |
DK (1) | DK1861120T3 (fr) |
EA (3) | EA011393B1 (fr) |
ES (1) | ES2585810T3 (fr) |
HR (1) | HRP20160816T1 (fr) |
HU (1) | HUE027837T2 (fr) |
IL (3) | IL185901A0 (fr) |
MA (3) | MA30298B1 (fr) |
MX (3) | MX2007011756A (fr) |
NO (3) | NO20074638L (fr) |
NZ (2) | NZ561822A (fr) |
PE (3) | PE20061300A1 (fr) |
PL (1) | PL1861120T3 (fr) |
PT (1) | PT1861120T (fr) |
SI (1) | SI1861120T1 (fr) |
TW (3) | TW200722101A (fr) |
WO (3) | WO2006100109A1 (fr) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8221761B1 (en) * | 1999-02-26 | 2012-07-17 | Novartis Ag | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing CG motifs |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US20100221284A1 (en) * | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
JP5869744B2 (ja) | 2005-03-23 | 2016-02-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Cd4t細胞および/または改善された記憶b細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用 |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
PL1951300T3 (pl) * | 2005-11-04 | 2012-03-30 | Novartis Ag | Zmiana równowagi TH1/TH2 w szczepionkach typu split przeciwko grypie zawierających adjuwant |
US20110180430A1 (en) * | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
CA2628152C (fr) * | 2005-11-04 | 2016-02-02 | Novartis Vaccines And Diagnostics S.R.L. | Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire |
EA014028B1 (ru) * | 2005-11-04 | 2010-08-30 | Новартис Вэксинс Энд Диагностикс Срл | Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа |
FR2896162B1 (fr) * | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
EP2476432B1 (fr) | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions incluant de l'hémagglutinine, procédés pour leur fabrication et leurs méthodes d'utilisation |
EP2004226A1 (fr) * | 2006-03-24 | 2008-12-24 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Stockage de vaccins antigrippaux sans refrigeration |
CN101500603A (zh) * | 2006-06-15 | 2009-08-05 | 诺华有限公司 | 节省佐剂的多剂量流感疫苗接种方案 |
CA2583555C (fr) * | 2006-07-17 | 2020-01-07 | Glaxosmithkline Biologicals S.A. | Vaccin contre la grippe |
KR101696727B1 (ko) * | 2006-07-17 | 2017-01-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 인플루엔자 백신 |
PL2422810T3 (pl) * | 2006-07-17 | 2015-03-31 | Glaxosmithkline Biologicals Sa | Szczepionka przeciw grypie |
EP2086582B1 (fr) * | 2006-10-12 | 2012-11-14 | GlaxoSmithKline Biologicals s.a. | Vaccin comprenant une emulsion adjuvante huile en l'eau |
CN101522218B (zh) * | 2006-10-12 | 2012-09-26 | 葛兰素史密丝克莱恩生物有限公司 | 包含水包油乳液佐剂的疫苗 |
GB0622282D0 (en) | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
EP1923070A1 (fr) * | 2006-11-15 | 2008-05-21 | Intervet International BV | Vaccin pour vacciner un félin contre le virus influenza |
NZ577405A (en) * | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
EP1938835A1 (fr) * | 2006-12-29 | 2008-07-02 | Pevion Biotech AG | Agent immunostimulant non spécifique |
NZ710459A (en) * | 2007-02-23 | 2016-06-24 | Baylor Res Inst | Therapeutic applications of activation of human antigen-presenting cells through dectin-1 |
TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
SG185294A1 (en) * | 2007-10-12 | 2012-11-29 | Csl Ltd | Method of eliciting an immune response against pandemic influenza virus |
JP5701058B2 (ja) * | 2007-10-19 | 2015-04-15 | ノバルティス アーゲー | 髄膜炎菌ワクチン処方物 |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
EP2227251A1 (fr) * | 2007-12-06 | 2010-09-15 | GlaxoSmithKline Biologicals SA | Composition contre la grippe |
US8466259B2 (en) * | 2007-12-07 | 2013-06-18 | National Health Research Institutes | Adjuvants |
TWI376385B (en) * | 2007-12-07 | 2012-11-11 | Nat Health Research Institutes | Production of lipidated proteins in e. coli |
EP2268309B1 (fr) * | 2008-03-18 | 2015-01-21 | Novartis AG | Améliorations dans la préparation des antigènes pour le vaccin contre le virus de la grippe |
ES2594102T3 (es) | 2008-04-18 | 2016-12-15 | Vaxinnate Corporation | Mutantes por deleción de la flagelina y métodos para su uso |
GB0905570D0 (en) * | 2009-03-31 | 2009-05-13 | Novartis Ag | Combined vaccines |
US9421251B2 (en) | 2008-06-25 | 2016-08-23 | Novartis Ag | Rapid responses to delayed booster immunisations |
US20120093859A1 (en) | 2009-02-10 | 2012-04-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
DK2396032T3 (en) | 2009-02-10 | 2016-12-19 | Seqirus Uk Ltd | Influenza vaccines with reduced amounts of squalene |
AU2015203072B2 (en) * | 2009-02-10 | 2017-05-25 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
US8287880B2 (en) * | 2009-06-02 | 2012-10-16 | National Health Research Institutes | Lipidated vaccine against dengue virus infection |
TWI409275B (zh) * | 2009-06-22 | 2013-09-21 | Nat Health Research Institutes | 脂質化腫瘤相關抗原及其免疫治療的組成物及方法 |
EP2289575B1 (fr) * | 2009-08-06 | 2017-07-05 | Biotronik VI Patent AG | Implant médical contenant une substance anti-oxydante |
IN2012DN00781A (fr) * | 2009-08-12 | 2015-06-26 | Sigmoid Pharma Ltd | |
EP2308506A1 (fr) * | 2009-10-02 | 2011-04-13 | Mucosis B.V. | Formulations de vaccin intranasal avec adjuvants |
GB0918830D0 (en) | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
DE102009056871A1 (de) | 2009-12-03 | 2011-06-22 | Novartis AG, 4056 | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
SI2380558T2 (sl) * | 2009-12-03 | 2019-11-29 | Novartis Ag | Izdelava emulzije z razmestitvijo interakcijske in protitlačne komore za mikrofluidizacijo |
DE102009056884B4 (de) | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
AU2013202690B2 (en) * | 2009-12-03 | 2016-02-11 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
DE102009056883B4 (de) | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
EP2356983B1 (fr) | 2009-12-03 | 2013-02-20 | Novartis AG | Circulation de composants pendant l'homogénéisation d'émulsions |
CL2012001399A1 (es) | 2009-12-03 | 2013-03-08 | Novartis Ag | Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion. |
NZ599881A (en) * | 2009-12-03 | 2014-01-31 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
KR20120107121A (ko) * | 2009-12-22 | 2012-09-28 | 사노피 파스퇴르 리미티드 | 면역원성 조성물 |
AU2011203740B2 (en) * | 2010-01-06 | 2014-11-13 | Vaxinnate Corporation | Methods and compositions for providing protective immunity in the elderly |
WO2011088451A1 (fr) * | 2010-01-15 | 2011-07-21 | Novavax, Inc. | Utilisations de particules de type virus de la grippe (vlps) pour la caractérisation de l'activité neuraminidase et hémagglutinine |
RU2527688C2 (ru) * | 2010-02-27 | 2014-09-10 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностого антигена н1n1 и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена н1n1 |
GB201009676D0 (en) * | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
GB201009671D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
GB201009673D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
US9821051B1 (en) | 2010-10-28 | 2017-11-21 | Seqirus UK Limited | Reducing hospitalization in elderly influenza vaccine recipients |
TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
TWI507413B (zh) * | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
WO2012116714A1 (fr) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination chez des patients âgés |
EP3566715A1 (fr) * | 2012-12-28 | 2019-11-13 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Composition de vaccin contre la grippe nasale |
EP2801372A3 (fr) * | 2013-05-10 | 2015-02-18 | Novartis AG | Éviter le risque de narcolepsie dans des vaccins contre la grippe |
US10080792B2 (en) * | 2013-09-23 | 2018-09-25 | Engen Bio, Inc. | Influenza vaccine and therapy |
CN104436157A (zh) * | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
AU2015323334B2 (en) | 2014-09-26 | 2021-02-25 | Seqirus UK Limited | Vaccination of immunocompromised subjects |
WO2019108928A1 (fr) * | 2017-11-30 | 2019-06-06 | Ohio State Innovation Foundation | Système d'administration de vaccin contre le virus de la grippe piégé par des nanoparticules mucoadhésives |
WO2020160080A1 (fr) | 2019-01-30 | 2020-08-06 | Glaxosmithkline Llc | Mélanges huile/tensioactif pour auto-émulsification |
WO2021123117A1 (fr) * | 2019-12-20 | 2021-06-24 | Fresenius Kabi Austria Gmbh | Procédé de production d'émulsions huile dans l'eau |
RU2741003C1 (ru) * | 2020-03-27 | 2021-01-22 | Евгений Дмитриевич Некрасов | Способ производства четырехвалентной субъединичной вакцины против гриппа без адъювантов |
EP4171629A1 (fr) | 2020-06-29 | 2023-05-03 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
CA3190375A1 (fr) | 2020-08-24 | 2022-03-03 | Natalie ANOSOVA | Vaccins contre la covid-19 avec des adjuvants d'emulsion de squalene contenant du tocopherol |
MX2023002339A (es) | 2020-08-24 | 2023-03-22 | Sanofi Pasteur Inc | Vacunas contra infecciones por sars-cov-2. |
KR102270165B1 (ko) | 2020-10-22 | 2021-06-28 | 한국화학연구원 | 세정제 조성물 |
US20240165224A1 (en) | 2021-03-26 | 2024-05-23 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
WO2023274860A1 (fr) | 2021-06-28 | 2023-01-05 | Glaxosmithkline Biologicals Sa | Nouveaux antigènes de la grippe |
RU2766292C1 (ru) * | 2021-08-05 | 2022-03-14 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) | Состав вакцины против covid-19 |
WO2023020993A1 (fr) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Nouveaux procédés |
WO2023020994A1 (fr) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Nouveaux procédés |
WO2023020992A1 (fr) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Nouveaux procédés |
WO2023061993A1 (fr) | 2021-10-13 | 2023-04-20 | Glaxosmithkline Biologicals Sa | Polypeptides |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3095974A (en) * | 1961-10-27 | 1963-07-02 | Anthony R Perini | Collapsible book rack |
US4047869A (en) * | 1973-02-23 | 1977-09-13 | Mulvany Jr R F | Apparatus for forming plastic articles |
FR2333610A1 (fr) * | 1975-12-03 | 1977-07-01 | Zhdanovsky Z Tyazhelogo Mash | Bande-electrode a ame en poudre pour rechargement a l'aide d'un alliage resistant a l'usure |
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
DD155875A1 (de) | 1980-12-31 | 1982-07-14 | Willy Nordheim | Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes |
US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) * | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
DD211444A3 (de) | 1982-08-19 | 1984-07-11 | Saechsisches Serumwerk | Verfahren zur herstellung von influenza-impfstoffen |
GB8300467D0 (en) | 1983-01-08 | 1983-02-09 | Wellcome Found | Equine influenza |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
DD300833A7 (de) | 1985-10-28 | 1992-08-13 | Saechsische Landesgewerbefoerd | Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen |
CA1283827C (fr) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Dispositif pour l'injection de formules liquides |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
JP2851288B2 (ja) | 1987-06-05 | 1999-01-27 | アメリカ合衆国 | 癌診断および管理における自己分泌運動性因子 |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
DE3734306A1 (de) | 1987-10-10 | 1989-04-27 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung fuer fliessfaehige medien |
US5376369A (en) * | 1987-11-03 | 1994-12-27 | Syntex (U.S.A.) Inc. | Vaccine adjuvant |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8821049D0 (en) | 1988-09-08 | 1988-10-05 | Health Lab Service Board | Method & composition for treatment & prevention of viral infections |
FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
EP0382271B1 (fr) * | 1989-02-04 | 1994-12-21 | Akzo Nobel N.V. | Tocols comme adjuvants de vaccins |
US5092235A (en) | 1989-05-24 | 1992-03-03 | Tektronix, Inc. | Pressure fixing and developing apparatus |
CA2017507C (fr) * | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant constitue d'une emulsion de gouttelettes submicron d'huile |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
DE4005528C2 (de) | 1990-02-22 | 1998-01-15 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
US5969109A (en) * | 1990-02-28 | 1999-10-19 | Bona; Constantin | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes |
WO1991013261A1 (fr) | 1990-03-02 | 1991-09-05 | Experimentalny Nauchno-Issledovatelsky Institut Metallorezhuschikh Stankov | Systeme numerique d'entrainement asservi |
US5149531A (en) * | 1990-06-27 | 1992-09-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
GB9105992D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
CN1124013A (zh) * | 1993-02-19 | 1996-06-05 | 史密丝克莱恩比彻姆公司 | 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物 |
CA2156525A1 (fr) | 1993-02-19 | 1994-09-01 | Susan Dillon | Compositions a base de lipide a monophosphoryle 3-o-desacyle pour des vaccins anti-grippe |
HU219056B (hu) | 1993-03-23 | 2001-02-28 | Smithkline Beecham Biologicals Sa | 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény |
US5762939A (en) * | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
DK0729473T3 (da) | 1993-11-17 | 2000-10-30 | Deutsche Om Arzneimittel Gmbh | Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
JP3836874B2 (ja) | 1994-02-24 | 2006-10-25 | ノババックス インコーポレイテッド | 免疫アジュバントとして少ラメラ脂質小胞を含むワクチン |
WO1995024176A1 (fr) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Dispositif de remplissage d'ampoule |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
WO1995026204A1 (fr) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
US5916879A (en) | 1996-11-12 | 1999-06-29 | St. Jude Children's Research Hospital | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
DE69838992T2 (de) * | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
DE69933200T2 (de) * | 1998-03-09 | 2007-02-22 | Glaxosmithkline Biologicals S.A. | Kombinierte impfstoffzusammensetzungen |
US6838269B1 (en) | 1998-04-15 | 2005-01-04 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
WO1999056776A2 (fr) | 1998-05-07 | 1999-11-11 | Corixa Corporation | Composition d'adjuvant et procedes d'utilisation de celle-ci |
EP1089913A1 (fr) | 1998-06-08 | 2001-04-11 | SCA Emballage France | Emballage a remise a plat rapide |
AU761396B2 (en) | 1998-06-30 | 2003-06-05 | Om Pharma | Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same |
AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
EP1574210B1 (fr) | 1999-02-26 | 2016-04-06 | Novartis Vaccines and Diagnostics, Inc. | Microemulsions à macromolécules adsorbées |
FR2796291B1 (fr) | 1999-07-16 | 2001-09-21 | Cross Site Technologies | Seringue sans aiguille munie d'un systeme de declenchement piezo-electrique |
FR2796290B1 (fr) | 1999-07-16 | 2001-09-14 | Cross Site Technologies | Seringue sans aiguille fonctionnant avec un generateur d'onde de choc a travers une paroi |
FR2796289B1 (fr) | 1999-07-16 | 2001-08-10 | Cross Site Technologies | Seringue sans aiguille avec injecteur a elements superposes |
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
FR2800619B1 (fr) | 1999-11-05 | 2002-02-08 | Cross Site Technologies | Seringue sans aiguille avec un moyen de poussee temporairement retenu |
FR2802102B1 (fr) | 1999-12-08 | 2002-07-12 | Poudres & Explosifs Ste Nale | Seringue sans aiguille munie d'un tube d'ejection a section constante |
FR2802103B1 (fr) | 1999-12-08 | 2003-10-03 | Poudres & Explosifs Ste Nale | Seringue sans aiguille fonctionnant avec entrainement du principe actif par effet tube a choc |
AU1581400A (en) | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
FR2802820B1 (fr) | 1999-12-27 | 2002-10-18 | Poudres & Explosifs Ste Nale | Seringue sans aiguille fonctionnant par effet tube a choc, avec maintien prealable du principe actif sur le cote |
PL211762B1 (pl) | 2000-01-31 | 2012-06-29 | Smithkline Beecham Biolog | Zastosowanie białka fuzyjnego zawierającego białka HIV Tat i HIV Nef lub polinukleotyd kodujący takie białko, białka lub polinukleotydu HIV gp120, białka lub polinukleotydu SIV Nef, adiuwanta indukującego TH1 zawierającego monofosforylolipid A lub jego pochodną i adiuwanta saponinowego oraz kompozycja szczepionki |
FR2804329B1 (fr) | 2000-02-02 | 2002-12-13 | Poudres & Explosifs Ste Nale | Seringue sans aiguille munie d'un opercule contenant le principe actif |
FR2804869B1 (fr) | 2000-02-11 | 2002-05-17 | Poudres & Explosifs Ste Nale | Seringue sans aiguille pour l'injection d'un liquide contenu dans une ampoule pre-remplie |
FR2805749B1 (fr) | 2000-03-01 | 2002-05-17 | Poudres & Explosifs Ste Nale | Seringue sans aiguille a deux niveaux de vitesse d'injection |
FR2807946B1 (fr) | 2000-04-19 | 2002-06-07 | Poudres & Explosifs Ste Nale | Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition |
FR2809626B1 (fr) | 2000-05-30 | 2003-03-07 | Poudres & Explosifs Ste Nale | Seringue sans aiguille avec membrane d'isolation d'un ejecteur multiconduit |
FR2810554B1 (fr) | 2000-06-22 | 2003-05-16 | Poudres & Explosifs Ste Nale | Seringue sans aiguille munie d'un reservoir modulable |
FR2812202B1 (fr) | 2000-07-28 | 2002-09-13 | Poudres & Explosifs Ste Nale | Seringue sans aiguille fonctionnant par mise en compression du reservoir contenant le principe actif liquide |
GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
FR2815544B1 (fr) | 2000-10-23 | 2003-02-14 | Poudres & Explosifs Ste Nale | Seringue sans aiguille securisee a architecture compacte |
EP1201250A1 (fr) | 2000-10-25 | 2002-05-02 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques |
PT1361890E (pt) | 2001-02-23 | 2011-06-07 | Glaxosmithkline Biolog Sa | Formulações vacinais de influenza para distribuição intradérmica |
MY134424A (en) * | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
US7361352B2 (en) * | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
AU2003224819A1 (en) * | 2002-04-01 | 2003-10-20 | Euro-Celtique S.A. | Epitope constructs comprising antigen presenting cell targeting mechanisms |
DE602004020189D1 (de) | 2003-01-30 | 2009-05-07 | Novartis Vaccines & Diagnostic | Adjuvante influenza-vakzine |
JP5600375B2 (ja) * | 2004-03-09 | 2014-10-01 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | インフルエンザウイルスワクチン |
US20090028903A1 (en) * | 2005-03-23 | 2009-01-29 | Glaxosmithkline Biologicals, S.A. | Novel use |
JP5869744B2 (ja) * | 2005-03-23 | 2016-02-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Cd4t細胞および/または改善された記憶b細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用 |
AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
WO2007052155A2 (fr) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
US9101578B2 (en) | 2006-05-01 | 2015-08-11 | Technovax, Inc. | Polyvalent influenza virus-like particle (VLP) compositions |
PL2422810T3 (pl) * | 2006-07-17 | 2015-03-31 | Glaxosmithkline Biologicals Sa | Szczepionka przeciw grypie |
KR101696727B1 (ko) | 2006-07-17 | 2017-01-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 인플루엔자 백신 |
CN101522218B (zh) * | 2006-10-12 | 2012-09-26 | 葛兰素史密丝克莱恩生物有限公司 | 包含水包油乳液佐剂的疫苗 |
TW200908994A (en) * | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
EP2227251A1 (fr) * | 2007-12-06 | 2010-09-15 | GlaxoSmithKline Biologicals SA | Composition contre la grippe |
-
2006
- 2006-03-21 JP JP2008502344A patent/JP5869744B2/ja active Active
- 2006-03-21 MX MX2007011756A patent/MX2007011756A/es active IP Right Grant
- 2006-03-21 AR ARP060101107A patent/AR054020A1/es not_active Application Discontinuation
- 2006-03-21 JP JP2008502346A patent/JP2008534467A/ja active Pending
- 2006-03-21 PT PT67238055T patent/PT1861120T/pt unknown
- 2006-03-21 WO PCT/EP2006/002836 patent/WO2006100109A1/fr active Application Filing
- 2006-03-21 PL PL06723805.5T patent/PL1861120T3/pl unknown
- 2006-03-21 KR KR1020077024383A patent/KR20070116651A/ko not_active Application Discontinuation
- 2006-03-21 EP EP11173265A patent/EP2397153A1/fr not_active Withdrawn
- 2006-03-21 TW TW095109708A patent/TW200722101A/zh unknown
- 2006-03-21 AR ARP060101108A patent/AR052625A1/es unknown
- 2006-03-21 MX MX2007011748A patent/MX2007011748A/es not_active Application Discontinuation
- 2006-03-21 KR KR1020077024388A patent/KR20070116652A/ko active Search and Examination
- 2006-03-21 TW TW095109703A patent/TW200700078A/zh unknown
- 2006-03-21 CA CA002602456A patent/CA2602456A1/fr not_active Abandoned
- 2006-03-21 US US11/909,351 patent/US20080181911A1/en not_active Abandoned
- 2006-03-21 HU HUE06723805A patent/HUE027837T2/en unknown
- 2006-03-21 NZ NZ561822A patent/NZ561822A/en not_active IP Right Cessation
- 2006-03-21 EP EP06723807A patent/EP1861122A1/fr not_active Withdrawn
- 2006-03-21 MX MX2007011775A patent/MX2007011775A/es not_active Application Discontinuation
- 2006-03-21 WO PCT/EP2006/002838 patent/WO2006100111A1/fr active Application Filing
- 2006-03-21 TW TW095109709A patent/TW200700079A/zh unknown
- 2006-03-21 NZ NZ561823A patent/NZ561823A/en not_active IP Right Cessation
- 2006-03-21 JP JP2008502345A patent/JP5770414B2/ja active Active
- 2006-03-21 CA CA2601022A patent/CA2601022C/fr active Active
- 2006-03-21 US US11/909,414 patent/US20090081253A1/en not_active Abandoned
- 2006-03-21 AU AU2006226543A patent/AU2006226543B2/en active Active
- 2006-03-21 SI SI200632082A patent/SI1861120T1/sl unknown
- 2006-03-21 EA EA200701785A patent/EA011393B1/ru not_active IP Right Cessation
- 2006-03-21 EP EP06723805.5A patent/EP1861120B1/fr active Active
- 2006-03-21 PE PE2006000311A patent/PE20061300A1/es not_active Application Discontinuation
- 2006-03-21 CA CA2603180A patent/CA2603180C/fr active Active
- 2006-03-21 ES ES06723805.5T patent/ES2585810T3/es active Active
- 2006-03-21 KR KR1020077024380A patent/KR20070116650A/ko not_active Application Discontinuation
- 2006-03-21 KR KR1020137034497A patent/KR101916787B1/ko active IP Right Grant
- 2006-03-21 AR ARP060101106A patent/AR053833A1/es not_active Application Discontinuation
- 2006-03-21 AU AU2006226459A patent/AU2006226459A1/en not_active Abandoned
- 2006-03-21 KR KR1020167014235A patent/KR20160064249A/ko not_active Application Discontinuation
- 2006-03-21 EP EP06723806A patent/EP1863529A1/fr not_active Withdrawn
- 2006-03-21 EA EA200701786A patent/EA011419B1/ru not_active IP Right Cessation
- 2006-03-21 WO PCT/EP2006/002837 patent/WO2006100110A1/fr active Application Filing
- 2006-03-21 US US11/909,388 patent/US20080171063A1/en not_active Abandoned
- 2006-03-21 PE PE2006000312A patent/PE20061428A1/es not_active Application Discontinuation
- 2006-03-21 EA EA200701787A patent/EA200701787A1/ru unknown
- 2006-03-21 AU AU2006226458A patent/AU2006226458B2/en active Active
- 2006-03-21 DK DK06723805.5T patent/DK1861120T3/en active
- 2006-03-23 PE PE2006000334A patent/PE20061387A1/es not_active Application Discontinuation
-
2007
- 2007-09-11 IL IL185901A patent/IL185901A0/en unknown
- 2007-09-11 IL IL185897A patent/IL185897A/en active IP Right Grant
- 2007-09-11 IL IL185906A patent/IL185906A0/en unknown
- 2007-09-12 NO NO20074638A patent/NO20074638L/no not_active Application Discontinuation
- 2007-09-12 NO NO20074635A patent/NO20074635L/no not_active Application Discontinuation
- 2007-09-24 MA MA30238A patent/MA30298B1/fr unknown
- 2007-09-24 MA MA30240A patent/MA29715B1/fr unknown
- 2007-09-24 MA MA30241A patent/MA29342B1/fr unknown
- 2007-09-28 NO NO20074930A patent/NO20074930L/no not_active Application Discontinuation
-
2011
- 2011-04-28 US US13/096,180 patent/US20110287054A1/en not_active Abandoned
-
2014
- 2014-01-31 JP JP2014016254A patent/JP2014129359A/ja active Pending
- 2014-08-21 US US14/465,055 patent/US9730999B2/en active Active
-
2016
- 2016-07-07 HR HRP20160816TT patent/HRP20160816T1/hr unknown
- 2016-08-05 CY CY20161100772T patent/CY1117874T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30298B1 (fr) | Composition | |
MA30624B1 (fr) | Vaccin anti-grippal | |
MA30866B1 (fr) | Vaccin | |
TW200716165A (en) | Novel vaccine formulations | |
MA31381B1 (fr) | Vaccin contre la grippe a emulsion huile dans l'eau | |
MA29321B1 (fr) | Vaccin a base de rotavirus vivant attenue pour administration orale | |
HUP0402067A2 (hu) | Oltóanyagok | |
MA29601B1 (fr) | Vaccin antipaludeen | |
CL2007001698A1 (es) | Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis. | |
MA30023B1 (fr) | Nouvelle composition | |
CY1116904T1 (el) | Εμβολιο | |
BRPI0510570A (pt) | composição de vacina | |
WO2012061599A2 (fr) | Vaccins contre toxoplasma gondii | |
Goyal et al. | Adjuvanted vaccines driven protection against visceral infection in BALB/c mice by Leishmania donovani | |
Skene et al. | Evaluation of ISCOMATRIX™ and ISCOM™ vaccines for immunisation against Helicobacter pylori | |
JP2008505130A (ja) | レプトスピラ属感染の治療による多発性硬化症の治療及び予防方法 | |
CY1113746T1 (el) | Εμβολιο που περιλαμβανει ανοσοενισχυτικο γαλακτωμα ελαιου σε υδωρ | |
WO2021257695A3 (fr) | Procédés et compositions liés à la neutralisation d'anticorps contre le coronavirus humain | |
MA32080B1 (fr) | Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1 | |
García et al. | Evaluation of immune responses raised against Tc13 antigens of Trypanosoma cruzi in the outcome of murine experimental infection | |
SG139618A1 (en) | Influenza vaccine | |
MX2009010963A (es) | Vacuna de influenza de emulsion de aceite en agua. | |
UA95646C2 (ru) | Вакцина, которая включает адъювант на основе эмульсии масло-в-воде | |
SG160386A1 (en) | Novel composition | |
BRPI0609516B8 (pt) | uso de um vírus de influenza ou preparação antigênica do mesmo |